VHHs as tools for therapeutic protein delivery to the central nervous system

Abstract

Background The blood brain barrier (BBB) limits the therapeutic perspective for central nervous system (CNS) disorders. Previously we found an anti-mouse transferrin receptor (TfR) VHH (Nb62) that was able to deliver a biologically active neuropeptide into the CNS in mice. Here, we aimed to test its potential to shuttle a therapeutic relevant cargo. Since this VHH could not recognize the human TfR and hence its translational potential is limited, we also aimed to find and validate an anti-human transferrin VHH to deliver a therapeutic cargo into the CNS. Methods Alpaca immunizations with human TfR, and subsequent phage selection and screening for human TfR binding VHHs was performed to find a human TfR specific VHH (Nb188). Its ability to cross the BBB was determined by fusing it to neurotensin, a neuropeptide that reduces body temperature when present in the CNS but is not able to cross the BBB on its own. Next, the anti–β-secretase 1 (BACE1) 1A11 Fab and Nb62 or Nb188 were fused to an Fc domain to generate heterodimeric antibodies (1A11AM-Nb62 and 1A11AM-Nb188). These were then administered intravenously in wild-type mice and in mice in which the murine apical domain of the TfR was replaced by the human apical domain (hAPI KI). Pharmacokinetic and pharmacodynamic (PK/PD) studies were performed to assess the concentration of the heterodimeric antibodies in the brain over time and the ability to inhibit brain-specific BACE1 by analysing the brain levels of Aβ1–40. Results Selections and screening of a phage library resulted in the discovery of an anti-human TfR VHH (Nb188). Fusion of Nb188 to neurotensin induced hypothermia after intravenous injections in hAPI KI mice. In addition, systemic administration 1A11AM-Nb62 and 1A11AM-Nb188 fusions were able to reduce Aβ1-40 levels in the brain whereas 1A11AM fused to an irrelevant VHH did not. A PK/PD experiment showed that this effect could last for 3 days. Conclusion We have discovered an anti-human TfR specific VHH that is able to reach the CNS when administered systemically. In addition, both the currently discovered anti-human TfR VHH and the previously identified mouse-specific anti-TfR VHH, are both able to shuttle a therapeutically relevant cargo into the CNS. We suggest the mouse-specific VHH as a valuable research tool in mice and the human-specific VHH as a moiety to enhance the delivery efficiency of therapeutics into the CNS in human patients.

Therapeutic approaches to enhance natural killer cell cytotoxicity

“…The TriKE platform stands out for its utilization of a camelid sdAb/nanobody, resulting in enhanced IL-15 potency when compared to first-generation TriKE, which included a CD16 scFv ( 157 , 163 ). To date, caplacizumab, a bivalent nanobody designed to target von Willebrand factor for treating thrombotic thrombocytopenic purpura and thrombosis, remains the only FDA-approved nanobody ( 166 ). However, a CAR T cell armed with two nanobodies that target BCMA is approved for the treatment of multiple myeloma, and an anti-PDL1 nanobody has gained approval in China.…”

Unique Binding and Stabilization Mechanisms Employed By and Engineered Into Nanobodies

“…This nanobody feature allows guided optimization of nanobodies using only their primary sequence, as demonstrated by our affinity and stability enhancement of potentially therapeutic nanobodies against SARS-CoV-2 with a single point mutation. With the growing interest in utilizing nanobody technology [35][36][37][38][39][40][41] , we hope this study will aid researchers to maximally utilize their nanobody repertoires and rationally engineer them, including for use as diagnostics, prophylactics and therapeutics.…”

Enhanced in vivo blood brain barrier transcytosis of macromolecular cargo using an engineered pH-sensitive mouse transferrin receptor binding nanobody

“…Additional nanobody-based therapeutics approved for human use include ciltacabtagene autoleucel which targets B-cell maturation antigen for multiple myeloma [ 24 ], envafolimab which targets programmed death ligand 1 for solid tumors [ 25 ] and ozoralizumab which targets tumor necrosis factor alpha for rheumatoid arthritis [ 26 ]. Other researchers have developed nanobody-based BBB transcytosis reagents that bind to TMEM30 [ 15 ], TfR [ 27 , 28 ], and IGF1R [ 10 , 11 ].…”